PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8625298-0	1996	13-cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro.	Isotretinoin	0-20	interferon alpha 2	Homo sapiens	26-45	
15943494-5	2005	A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.	Isotretinoin	101-113	interferon alpha 2	Homo sapiens	43-62	
15943494-5	2005	A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.	Isotretinoin	101-113	interferon alpha 2	Homo sapiens	43-62	
12804041-2	2003	Because of the enhancement of the antiproliferative effects of interferon-alpha2a, 13-cis-retinoic acid (13-CRA) might be of potential usefulness for immunotherapy.	Isotretinoin	83-103	interferon alpha 2	Homo sapiens	63-81	
11943887-2	2002	Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week.	Isotretinoin	57-77	interferon alpha 2	Homo sapiens	100-118	
11943887-2	2002	Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week.	Isotretinoin	79-82	interferon alpha 2	Homo sapiens	100-118